Published in J Exp Med on September 01, 1991
Macrophage deactivation by interleukin 10. J Exp Med (1991) 6.94
Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev (1998) 4.03
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med (1994) 2.86
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 2.84
Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun (1994) 2.35
Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun (1996) 2.18
Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun (1994) 1.99
Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun (1995) 1.94
Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun (1996) 1.93
Role of nitric oxide in parasitic infections. Microbiol Rev (1995) 1.91
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A (1993) 1.76
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med (1998) 1.57
Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies. Infect Immun (2003) 1.54
In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc Natl Acad Sci U S A (1997) 1.53
Induction of transforming growth factor beta 1 by purified protein derivative of Mycobacterium tuberculosis. Infect Immun (1995) 1.52
Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med (1994) 1.43
IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis (2010) 1.37
Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. J Exp Med (1992) 1.37
Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am J Pathol (2001) 1.36
Interleukin-12-mediated resistance to Trypanosoma cruzi is dependent on tumor necrosis factor alpha and gamma interferon. Infect Immun (1996) 1.30
Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol (2012) 1.26
In vivo regulation of nitric oxide production by tumor necrosis factor alpha and gamma interferon, but not by interleukin-4, during blood stage malaria in mice. Infect Immun (1996) 1.24
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease. J Exp Med (1995) 1.18
Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 1.17
Impairment of the cellular immune response in acute murine toxoplasmosis: regulation of interleukin 2 production and macrophage-mediated inhibitory effects. Infect Immun (1994) 1.14
Production of TNF-alpha, IL-6 and TGF-beta, and expression of receptors for TNF-alpha and IL-6, during murine Mycobacterium avium infection. Immunology (1995) 1.14
Successive tick infestations selectively promote a T-helper 2 cytokine profile in mice. Immunology (1999) 1.08
Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Infect Immun (1999) 1.08
Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol (1995) 1.05
Transforming growth factor beta-induced failure of resistance to infection with blood-stage Plasmodium chabaudi in mice. Infect Immun (1999) 1.03
Infection of murine macrophages with Toxoplasma gondii is associated with release of transforming growth factor beta and downregulation of expression of tumor necrosis factor receptors. Infect Immun (1993) 1.02
Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas' disease. Antimicrob Agents Chemother (2009) 1.02
Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages. Immunology (1995) 1.01
Leukotriene B(4) induces nitric oxide synthesis in Trypanosoma cruzi-infected murine macrophages and mediates resistance to infection. Infect Immun (2002) 1.01
Pathogenesis of Chagas disease: time to move on. Front Biosci (Elite Ed) (2012) 1.01
Dual role for transforming growth factor beta-dependent signaling in Trypanosoma cruzi infection of mammalian cells. Infect Immun (2000) 1.01
Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains. Infect Immun (1998) 1.01
Interferon-gamma-induced nitric oxide causes intrinsic intestinal denervation in Trypanosoma cruzi-infected mice. Am J Pathol (2004) 0.98
Ascorbate peroxidase from Leishmania major controls the virulence of infective stage of promastigotes by regulating oxidative stress. PLoS One (2010) 0.98
Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J Clin Invest (2007) 0.98
Role of SOCS2 in modulating heart damage and function in a murine model of acute Chagas disease. Am J Pathol (2012) 0.96
IL-10 inhibits the NF-κB and ERK/MAPK-mediated production of pro-inflammatory mediators by up-regulation of SOCS-3 in Trypanosoma cruzi-infected cardiomyocytes. PLoS One (2013) 0.95
Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun (1995) 0.95
Immune Evasion Strategies of Trypanosoma cruzi. J Immunol Res (2015) 0.95
Response to stimulation with recombinant cytokines and synthesis of cytokines by murine intestinal macrophages infected with the Mycobacterium avium complex. Infect Immun (1995) 0.94
B cells modulate T cells so as to favour T helper type 1 and CD8+ T-cell responses in the acute phase of Trypanosoma cruzi infection. Immunology (2007) 0.94
Chagas disease cardiomyopathy: immunopathology and genetics. Mediators Inflamm (2014) 0.93
Uptake of host cell transforming growth factor-beta by Trypanosoma cruzi amastigotes in cardiomyocytes: potential role in parasite cycle completion. Am J Pathol (2005) 0.92
Activation of transforming growth factor beta by malaria parasite-derived metalloproteinases and a thrombospondin-like molecule. J Exp Med (2003) 0.89
Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Infect Immun (1996) 0.88
SB-431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion. Antimicrob Agents Chemother (2007) 0.88
Trypanosoma cruzi induces regulatory dendritic cells in vitro. Infect Immun (2008) 0.88
Microbes-induced EMT at the crossroad of inflammation and cancer. Gut Microbes (2012) 0.87
Transforming growth factor-beta expression in human retinal pigment epithelial cells is enhanced by Toxoplasma gondii: a possible role in the immunopathogenesis of retinochoroiditis. Clin Exp Immunol (2002) 0.86
Different parasite inocula determine the modulation of the immune response and outcome of experimental Trypanosoma cruzi infection. Immunology (2013) 0.85
Expression of TGF-beta in attenuated Salmonella typhimurium: oral administration leads to the reduction of inflammation, IL-2 and IFN-gamma, but enhancement of IL-10, in carrageenin-induced oedema in mice. Immunology (1995) 0.84
Lipid bodies: inflammatory organelles implicated in host-Trypanosoma cruzi interplay during innate immune responses. Mediators Inflamm (2012) 0.83
Neurotrophin receptor TrkC is an entry receptor for Trypanosoma cruzi in neural, glial, and epithelial cells. Infect Immun (2011) 0.82
Interferon-γ and other inflammatory mediators in cardiomyocyte signaling during Chagas disease cardiomyopathy. World J Cardiol (2014) 0.82
Detection of transforming growth factor-beta 1 in dermal lesions of different clinical forms of leprosy. Am J Pathol (1996) 0.81
Transforming growth factor beta 1 and gamma interferon provide opposing signals to lipopolysaccharide-activated mouse macrophages. Infect Immun (1994) 0.81
Genes from Chagas susceptibility loci that are differentially expressed in T. cruzi-resistant mice are candidates accounting for impaired immunity. PLoS One (2006) 0.81
Invasive candidiasis stimulates hepatocyte and monocyte production of active transforming growth factor beta. Infect Immun (2001) 0.81
CD4+ CD25+ FOXP3+ Treg cells induced by rSSP4 derived from T. cruzi amastigotes increase parasitemia in an experimental Chagas disease model. Biomed Res Int (2012) 0.80
Production of transforming growth factor-beta 1 (TGF-beta1) by blood monocytes from patients with different clinical forms of leprosy. Clin Exp Immunol (2000) 0.80
A parent-of-origin effect determines the susceptibility of a non-informative F1 population to Trypanosoma cruzi infection in vivo. PLoS One (2013) 0.79
A phosphoproteomic approach towards the understanding of the role of TGF-β in Trypanosoma cruzi biology. PLoS One (2012) 0.79
Specific antibodies induce apoptosis in Trypanosoma cruzi epimastigotes. Parasitol Res (2010) 0.79
Trypanosoma cruzi infection and host lipid metabolism. Mediators Inflamm (2014) 0.78
Effect of transforming growth factor beta on experimental Salmonella typhimurium infection in mice. Infect Immun (1999) 0.77
Differential Activation of Human Monocytes and Lymphocytes by Distinct Strains of Trypanosoma cruzi. PLoS Negl Trop Dis (2015) 0.77
Early expression of local cytokines during systemic Candida albicans infection in a murine intravenous challenge model. Biomed Rep (2014) 0.76
3-Hydroxy kynurenine treatment controls T. cruzi replication and the inflammatory pathology preventing the clinical symptoms of chronic Chagas disease. PLoS One (2011) 0.76
Transforming growth factor-beta 1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica. Immunology (1995) 0.76
Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable! Front Immunol (2016) 0.75
Evasion and Immuno-Endocrine Regulation in Parasite Infection: Two Sides of the Same Coin in Chagas Disease? Front Microbiol (2016) 0.75
Concepts of immunostimulation to increase antiparasitic drug action. Parasitol Res (2003) 0.75
Canine Macrophage DH82 Cell Line As a Model to Study Susceptibility to Trypanosoma cruzi Infection. Front Immunol (2017) 0.75
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A (1987) 6.76
Deactivation of macrophages by transforming growth factor-beta. Nature (1988) 5.56
Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med (1979) 5.22
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol (1990) 3.55
Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol (1988) 2.74
Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol (1988) 2.70
In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol (1988) 2.59
Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol (1986) 2.53
Modulation of cytokine production by transforming growth factor-beta. J Immunol (1989) 2.42
Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med (1987) 1.85
Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J Immunol (1991) 1.71
Enhancing effects of gamma interferon on phagocytic cell association with and killing of Trypanosoma cruzi. Infect Immun (1985) 1.62
Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro. Eur J Immunol (1984) 1.58
Restoration of in vitro immune responses of spleen cells from mice infected with Trypanosoma cruzi by supernatants containing interleukin 2. J Immunol (1984) 1.53
Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2. J Immunol (1984) 1.45
Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother (1988) 1.39
Heterologous antibody responses in mice with chronic T. cruzi infection: depressed T helper function restored with supernatants containing interleukin 2. J Immunol (1984) 1.35
Spleen cell-mediated suppression of IgG production to a non-parasite antigen during chronic Trypanosoma cruzi infection in mice. J Immunol (1983) 1.18
Immune deficiency in chronic Trypanosoma cruzi infection. Recombinant IL-1 restores Th function for antibody production. J Immunol (1989) 1.17
Recombinant granulocyte-macrophage colony-stimulating factor restores deficient immune responses in mice with chronic Trypanosoma cruzi infections. J Immunol (1990) 1.12
Gamma-interferon-induced activation of latent transforming growth factor-beta by human monocytes. Ann N Y Acad Sci (1990) 1.08
Enhancement of tumor growth correlates with suppression of the tumor-specific cytolytic T lymphocyte response in mice chronically infected by Trypanosoma cruzi. J Immunol (1985) 1.04
Bone-derived and recombinant transforming growth factor beta's are potent inhibitors of tumor cell growth. Biochem Biophys Res Commun (1987) 1.00
Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J (1994) 3.92
Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science (1992) 3.71
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A (1993) 3.40
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
Transforming growth factors produced by retrovirus-transformed rodent fibroblasts and human melanoma cells: amino acid sequence homology with epidermal growth factor. Proc Natl Acad Sci U S A (1983) 3.21
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest (1991) 2.70
Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science (1986) 2.67
Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol (1995) 2.37
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol Cell Biol (1987) 2.26
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science (1987) 2.24
Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature (1985) 2.15
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 2.11
Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol (1988) 2.10
Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med (1998) 2.06
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res (2000) 1.98
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun (1996) 1.93
rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab Immunol (1998) 1.90
Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis (1987) 1.87
P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol (2001) 1.86
Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86
A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med (1995) 1.81
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A (1993) 1.76
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol (2000) 1.66
Transformation induced by Abelson murine leukemia virus involves production of a polypeptide growth factor. Science (1982) 1.66
Immunopathology of experimental cutaneous leishmaniasis. Am J Pathol (1984) 1.65
Mouse embryonic transforming growth factors related to those isolated from tumor cells. Cancer Res (1982) 1.61
Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med (2000) 1.60
Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun (1999) 1.55
Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol (2001) 1.54
Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report. Braz J Infect Dis (2001) 1.54
Cloning and sequence analysis of simian transforming growth factor-beta cDNA. DNA (1987) 1.54
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun (1998) 1.53
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun (2001) 1.51
Mechanism of suppression in Drosophila: a change in tyrosine transfer RNA. J Mol Biol (1971) 1.50
Regulation of T cell proliferation by IL-7. J Immunol (1990) 1.50
IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. J Immunol (1994) 1.46
Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2. J Immunol (1984) 1.45
Novel delivery system for inducing quiescence in intestinal stem cells in rats by transforming growth factor beta 1. Gastroenterology (1994) 1.44
Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis. J Clin Microbiol (2000) 1.44
A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis (1998) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. Proc Natl Acad Sci U S A (1985) 1.39
Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J Immunol (1998) 1.38
Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol (1999) 1.38
Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg (1990) 1.37
Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. J Exp Med (1992) 1.37
Heterologous antibody responses in mice with chronic T. cruzi infection: depressed T helper function restored with supernatants containing interleukin 2. J Immunol (1984) 1.35
Identification and synthesis of a major conserved antigenic epitope of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1992) 1.34
Vaccinia virus growth factor stimulates tyrosine protein kinase activity of A431 cell epidermal growth factor receptors. Mol Cell Biol (1986) 1.33
Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. Am J Trop Med Hyg (1983) 1.32
Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera. J Immunol (1987) 1.32
LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol (1998) 1.31
Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J Immunol (2000) 1.31
Suppression of cell-mediated immunity in experimental Chagas' disease. Z Parasitenkd (1977) 1.30
Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun (1998) 1.28
Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans R Soc Trop Med Hyg (1995) 1.27
Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha. Science (1985) 1.27
A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. J Infect Dis (1999) 1.25
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun (2002) 1.25
Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol (1996) 1.24
Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg (1986) 1.24
Inhibition of lymphocyte transformation by disrupted murine oncornavirus. Cancer Res (1977) 1.24
High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res (1983) 1.22
Expression and characterization of transforming growth factor alpha precursor protein in transfected mammalian cells. Mol Cell Biol (1987) 1.20
Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun (1995) 1.20
Transforming growth factors in the urine of normal, pregnant, and tumor-bearing humans. J Natl Cancer Inst (1982) 1.19
Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol (1998) 1.19
Spleen cell-mediated suppression of IgG production to a non-parasite antigen during chronic Trypanosoma cruzi infection in mice. J Immunol (1983) 1.18
Binding characteristics of Rauscher leukemia virus envelope glycoprotein gp71 to murine lymphoid cells. J Virol (1977) 1.18
Molecular karyotype of species and subspecies of Leishmania. Mol Biochem Parasitol (1986) 1.17
Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol (2001) 1.16
Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen. J Clin Microbiol (2001) 1.15
Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species. J Infect Dis (1993) 1.15
Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol (1995) 1.15
Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene (2000) 1.14
Detection of larger polypeptides structurally and functionally related to type I transforming growth factor. Proc Natl Acad Sci U S A (1985) 1.13
Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res (2001) 1.12
Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol (1991) 1.12
Leishmania gp63 molecule implicated in cellular adhesion lacks an Arg-Gly-Asp sequence. Mol Biochem Parasitol (1990) 1.10
Serodiagnosis of human granulocytic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins. J Clin Microbiol (2001) 1.10
Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses. J Immunol (1991) 1.09
Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol (1991) 1.09
Enzyme-linked immunosorbent assay for serological diagnosis of Chagas' disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides. J Clin Microbiol (2001) 1.09
Differential expression of transforming growth factor-alpha during prenatal development of the mouse. Cancer Res (1985) 1.08